CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam
- PMID:11159802
CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam
Abstract
The kinetics of flunitrazepam (FNTZ) N-demethylation to desmethylflunitrazepam (DM FNTZ), and 3-hydroxylation to 3-hydroxyflunitrazepam (3-OH FNTZ), were studied in human liver microsomes and in microsomes containing heterologously expressed individual human CYPs. FNTZ was N-demethylated by cDNA-expressed CYP2A6 (K(m) = 1921 microM), CYP2B6 (K(m) = 101 microM), CYP2C9 (K(m) = 50 microM), CYP2C19 (K(m) = 60 microM), and CYP3A4 (K(m) = 155 microM), and 3-hydroxylated by cDNA-expressed CYP2A6 (K(m) = 298 microM) and CYP3A4 (K(m) = 286 microM). The 3-hydroxylation pathway was predominant in liver microsomes, accounting for more than 80% of intrinsic clearance compared with the N-demethylation pathway. After adjusting for estimated relative abundance, CYP3A accounted for the majority of intrinsic clearance via both pathways. This finding was supported by chemical inhibition studies in human liver microsomes. Formation of 3-OH FNTZ was reduced to 10% or less of control values by ketoconazole (IC(50) = 0.11 microM) and ritonavir (IC(50) = 0.041 microM). Formation of DM FNTZ was inhibited to 40% of control velocity by 2.5 microM ketoconazole and to 30% of control by 2.5 microM ritonavir. Neither 3-OH FNTZ nor DM FNTZ formation was inhibited to less than 85% of control activity by alpha-naphthoflavone (CYP1A2), sulfaphenazole (CYP2C9), omeprazole (CYP2C19), or quinidine (CYP2D6). Thus, CYP-dependent FNTZ biotransformation, like that of many benzodiazepine derivatives, is mediated mainly by CYP3A. Clinical interactions of FNTZ with CYP3A inhibitors can be anticipated.
Similar articles
- Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.Venkatakrishnan K, von Moltke LL, Duan SX, Fleishaker JC, Shader RI, Greenblatt DJ.Venkatakrishnan K, et al.J Pharm Pharmacol. 1998 Mar;50(3):265-74. doi: 10.1111/j.2042-7158.1998.tb06859.x.J Pharm Pharmacol. 1998.PMID:9600717
- Flunitrazepam metabolism by cytochrome P450S 2C19 and 3A4.Kilicarslan T, Haining RL, Rettie AE, Busto U, Tyndale RF, Sellers EM.Kilicarslan T, et al.Drug Metab Dispos. 2001 Apr;29(4 Pt 1):460-5.Drug Metab Dispos. 2001.PMID:11259331
- In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes.Nielsen TL, Rasmussen BB, Flinois JP, Beaune P, Brosen K.Nielsen TL, et al.J Pharmacol Exp Ther. 1999 Apr;289(1):31-7.J Pharmacol Exp Ther. 1999.PMID:10086984
- Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.Khojasteh SC, Prabhu S, Kenny JR, Halladay JS, Lu AY.Khojasteh SC, et al.Eur J Drug Metab Pharmacokinet. 2011 Mar;36(1):1-16. doi: 10.1007/s13318-011-0024-2. Epub 2011 Feb 19.Eur J Drug Metab Pharmacokinet. 2011.PMID:21336516Review.
- Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes.Rodrigues AD.Rodrigues AD.Biochem Pharmacol. 1999 Mar 1;57(5):465-80. doi: 10.1016/s0006-2952(98)00268-8.Biochem Pharmacol. 1999.PMID:9952310Review.
Cited by
- Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients.Marie S, Frost KL, Hau RK, Martinez-Guerrero L, Izu JM, Myers CM, Wright SH, Cherrington NJ.Marie S, et al.Acta Pharm Sin B. 2023 Jan;13(1):1-28. doi: 10.1016/j.apsb.2022.08.018. Epub 2022 Aug 28.Acta Pharm Sin B. 2023.PMID:36815037Free PMC article.Review.
- Metabolites replace the parent drug in the drug arena. The cases of fonazepam and nifoxipam.Katselou M, Papoutsis I, Nikolaou P, Spiliopoulou C, Athanaselis S.Katselou M, et al.Forensic Toxicol. 2017;35(1):1-10. doi: 10.1007/s11419-016-0338-5. Epub 2016 Sep 17.Forensic Toxicol. 2017.PMID:28127407Free PMC article.Review.
- Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients.Wang A, Yu BN, Luo CH, Tan ZR, Zhou G, Wang LS, Zhang W, Li Z, Liu J, Zhou HH.Wang A, et al.Eur J Clin Pharmacol. 2005 Feb;60(12):843-8. doi: 10.1007/s00228-004-0848-7. Epub 2005 Jan 14.Eur J Clin Pharmacol. 2005.PMID:15650881Clinical Trial.
- Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.Yadav J, Korzekwa K, Nagar S.Yadav J, et al.Mol Pharm. 2018 May 7;15(5):1979-1995. doi: 10.1021/acs.molpharmaceut.8b00129. Epub 2018 Apr 10.Mol Pharm. 2018.PMID:29608318Free PMC article.
- Design, Synthesis and Characterization of HIV-1 CA-Targeting Small Molecules: Conformational Restriction of PF74.Sahani RL, Diana-Rivero R, Vernekar SKV, Wang L, Du H, Zhang H, Castaner AE, Casey MC, Kirby KA, Tedbury PR, Xie J, Sarafianos SG, Wang Z.Sahani RL, et al.Viruses. 2021 Mar 15;13(3):479. doi: 10.3390/v13030479.Viruses. 2021.PMID:33804121Free PMC article.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Medical